Drug Profile
RDC 5
Alternative Names: Chroneuro™; RDC5Latest Information Update: 30 Jun 2023
Price :
$50
*
At a glance
- Originator Chronos Therapeutics
- Class Neuroprotectants; Osteoporosis therapies
- Mechanism of Action Autophagy stimulants; Reactive oxygen species modulators; Synuclein inhibitors; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Neurodegenerative disorders; Obesity
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
- No development reported Neurodegenerative disorders
- Discontinued Obesity; Osteoporosis; Postmenopausal osteoporosis
Most Recent Events
- 27 Jun 2023 Phase-I clinical trials in Amyotrophic lateral sclerosis in United Kingdom (PO) (Chronos Therapeutics pipeline, March 2023)
- 27 Mar 2023 Discontinued - Preclinical for Obesity in United Kingdom (PO)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Obesity in United Kingdom (PO)